Eisai Zonegran Generics Launch
This article was originally published in The Pink Sheet Daily
FDA approved ten generic versions of Eisai's anti-epileptic Zonegran (zonisamide) Dec. 22
You may also be interested in...
Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.